Adding Spiriva Respimat effective for uncontrolled asthma, regardless of allergy subtype
Spiriva Respimat shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies.
Boehringer Ingelheim Pharmaceuticals has announced the presentation of new post-hoc analyses that show the addition of Spiriva Respimat to other asthma maintenance therapies helps improve lung function and asthma symptom control, while reducing asthma exacerbations (also known as flare-ups), independent of a patient's subtype of allergic asthma. These data were presented at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Los Angeles.
These analyses evaluated the safety and efficacy of adding Spiriva Respimat to other maintenance therapies compared to placebo across the broad range of asthma patients studied, regardless of immunoglobulin E (IgE) or eosinophil levels.
The addition of Spiriva respimat significantly improved lung function. Adding Spiriva Respimat also was shown to improve asthma symptom control, as measured by the seven question Asthma Control Questionnaire (ACQ-7) and reduce the risk of asthma worsening and exacerbations. The ACQ-7 results in the pooled analysis did not distinguish among the treatment arms.
"The data confirm that adding Spiriva Respimat is a well-tolerated and effective treatment option for asthma patients independent of allergic subtype," said Mark Vandewalker, director, Clinical Research of the Ozarks, Columbia, Missouri. "For people with allergic asthma who are still experiencing symptoms, adding Spiriva Respimat may help open airways to improve breathing."
People living with allergic asthma — the most common form of the condition — experience inflammation and a tightening of the airways due to exposure to common allergens. These patients may need other inhaled options that complement their existing therapy.
Spiriva Respimat is steroid-free and works differently than other therapies. When asthma symptoms persist despite taking other maintenance therapies, adding Spiriva Respimat may help people breathe better by opening constricted airways.
Spiriva Respimat is the first new class of inhaled medicine approved in over 10 years for asthma. The FDA approved a once-daily dose of Spiriva Respimat 2.5 µg (delivered in 2 puffs of 1.25 µg each) for the long-term maintenance treatment of asthma in people ages 12 and older. Spiriva Respimat is not a treatment for sudden asthma symptoms. In the treatment of asthma, the maximum benefits in lung function may take up to 4 to 8 weeks of dosing.
"Boehringer Ingelheim is committed to pursuing scientific research to help address unmet needs and improve patient care for people living with asthma," said Danny McBryan, vice president, Clinical Development & Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. "These data further demonstrate the benefits of Spiriva Respimat for the broad range of asthma patients studied who continued to experience symptoms despite taking other maintenance therapies, regardless of allergy subtype."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance